Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.20 Consensus Target Price from Analysts

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $36.20.

Several research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th. The Goldman Sachs Group raised their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, November 21st. Stifel Nicolaus raised their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, StockNews.com lowered shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd.

Institutional Trading of Syndax Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Assenagon Asset Management S.A. boosted its holdings in shares of Syndax Pharmaceuticals by 343.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock valued at $27,292,000 after acquiring an additional 1,598,428 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in shares of Syndax Pharmaceuticals during the 3rd quarter worth about $15,165,000. Eventide Asset Management LLC purchased a new stake in shares of Syndax Pharmaceuticals during the third quarter worth approximately $15,150,000. First Turn Management LLC raised its position in shares of Syndax Pharmaceuticals by 85.4% in the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock valued at $22,853,000 after buying an additional 546,776 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Syndax Pharmaceuticals by 56.3% in the second quarter. Millennium Management LLC now owns 1,065,508 shares of the company’s stock worth $21,875,000 after buying an additional 383,634 shares in the last quarter.

Syndax Pharmaceuticals Stock Down 1.1 %

NASDAQ SNDX opened at $14.25 on Wednesday. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -3.93 and a beta of 0.89. The business has a 50 day moving average price of $14.39 and a 200-day moving average price of $18.04. Syndax Pharmaceuticals has a 52 week low of $12.06 and a 52 week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the previous year, the firm earned ($0.73) earnings per share. On average, equities research analysts anticipate that Syndax Pharmaceuticals will post -3.71 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).